Primary HPV cervical cancer screening in the United States: Are we ready?

Ritu Nayar; Robert A. Goulart; Diane D. Davey

doi:10.1016/j.jasc.2017.12.001

Primary HPV cervical cancer screening in the United States: Are we ready?

Ritu Nayar^*, Robert A. Goulart, Diane D. Davey

^*Corresponding author for this work

Pathology

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

In September 2017, the United States Preventive Services Task Force put forth updated draft guidelines for cervical cancer screening in the United States, which were then open to public comment. The recommendations allowed for every-3-year cervical cytology screening in women aged 21 to 65 years with an option for every-5-year high-risk human papillomavirus testing in women aged 30 to 65 years. There was no option for cotesting. Other recommendations were similar to those published by other professional organizations. The Cytopathology Education and Technology Consortium provided an official response during the open comment period, which is summarized here along with additional commentary by the authors.

Original language	English (US)
Pages (from-to)	50-55
Number of pages	6
Journal	Journal of the American Society of Cytopathology
Volume	7
Issue number	1
DOIs	https://doi.org/10.1016/j.jasc.2017.12.001
State	Published - Jan 2018

Keywords

USPSTF guidelines
cervical cancer
primary HPV screening

ASJC Scopus subject areas

Pathology and Forensic Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jasc.2017.12.001

Cite this

@article{a3aec8f04c504f5d9d99869940e1b1a3,

title = "Primary HPV cervical cancer screening in the United States: Are we ready?",

abstract = "In September 2017, the United States Preventive Services Task Force put forth updated draft guidelines for cervical cancer screening in the United States, which were then open to public comment. The recommendations allowed for every-3-year cervical cytology screening in women aged 21 to 65 years with an option for every-5-year high-risk human papillomavirus testing in women aged 30 to 65 years. There was no option for cotesting. Other recommendations were similar to those published by other professional organizations. The Cytopathology Education and Technology Consortium provided an official response during the open comment period, which is summarized here along with additional commentary by the authors.",

keywords = "USPSTF guidelines, cervical cancer, primary HPV screening",

author = "Ritu Nayar and Goulart, {Robert A.} and Davey, {Diane D.}",

year = "2018",

month = jan,

doi = "10.1016/j.jasc.2017.12.001",

language = "English (US)",

volume = "7",

pages = "50--55",

journal = "Journal of the American Society of Cytopathology",

issn = "2213-2945",

publisher = "Elsevier BV",

number = "1",

}

TY - JOUR

T1 - Primary HPV cervical cancer screening in the United States

T2 - Are we ready?

AU - Nayar, Ritu

AU - Goulart, Robert A.

AU - Davey, Diane D.

PY - 2018/1

Y1 - 2018/1

N2 - In September 2017, the United States Preventive Services Task Force put forth updated draft guidelines for cervical cancer screening in the United States, which were then open to public comment. The recommendations allowed for every-3-year cervical cytology screening in women aged 21 to 65 years with an option for every-5-year high-risk human papillomavirus testing in women aged 30 to 65 years. There was no option for cotesting. Other recommendations were similar to those published by other professional organizations. The Cytopathology Education and Technology Consortium provided an official response during the open comment period, which is summarized here along with additional commentary by the authors.

AB - In September 2017, the United States Preventive Services Task Force put forth updated draft guidelines for cervical cancer screening in the United States, which were then open to public comment. The recommendations allowed for every-3-year cervical cytology screening in women aged 21 to 65 years with an option for every-5-year high-risk human papillomavirus testing in women aged 30 to 65 years. There was no option for cotesting. Other recommendations were similar to those published by other professional organizations. The Cytopathology Education and Technology Consortium provided an official response during the open comment period, which is summarized here along with additional commentary by the authors.

KW - USPSTF guidelines

KW - cervical cancer

KW - primary HPV screening

UR - http://www.scopus.com/inward/record.url?scp=85039037437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039037437&partnerID=8YFLogxK

U2 - 10.1016/j.jasc.2017.12.001

DO - 10.1016/j.jasc.2017.12.001

M3 - Article

C2 - 31043251

AN - SCOPUS:85039037437

SN - 2213-2945

VL - 7

SP - 50

EP - 55

JO - Journal of the American Society of Cytopathology

JF - Journal of the American Society of Cytopathology

IS - 1

ER -

Primary HPV cervical cancer screening in the United States: Are we ready?

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this